Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

Viking Therapeutics announced positive top-line results from its Phase 2 VENTURE-Oral Dosing trial for VK2735, its dual GLP-1/GIP agonist. The oral tablet demonstrated statistically significant body weight reductions, with patients achieving up to 12.2% mean weight loss after 13 weeks compared to 1.3% for placebo, and up to 80% reaching at least 10% weight loss. The drug was also safe and well-tolerated, with 99% of GI-related adverse events being mild or moderate, and an exploratory arm suggesting potential for low-dose weight maintenance. These robust results position oral VK2735 as a strong contender in the competitive obesity market, offering a convenient alternative to injectable therapies and potentially enhancing Viking's valuation.

Analysis

Viking Therapeutics has reported unequivocally positive top-line results from its Phase 2 trial of oral VK2735, a dual GLP-1/GIP agonist for obesity. The study successfully met its primary and secondary endpoints, demonstrating statistically significant, dose-dependent weight loss. At the highest dose, patients achieved a mean weight reduction of 12.2% (10.9% placebo-adjusted) over 13 weeks, with up to 80% of subjects reaching at least 10% weight loss, positioning the drug competitively within the GLP-1 landscape. Crucially, the weight loss trajectory did not plateau, suggesting potential for greater efficacy with longer treatment durations. The safety profile appears manageable and consistent with the drug class; while gastrointestinal side effects like nausea were common, 99% of these events were classified as mild or moderate. However, the patient discontinuation rate, which reached 38% at the highest dose, is a key metric to monitor as it could impact commercial viability. The exploratory data showing successful weight maintenance on a lower dose after an initial higher-dose period provides a strong proof-of-concept for a commercially attractive, long-term treatment strategy. These results significantly de-risk the asset and enhance Viking's strategic position as a developer of a potential best-in-class oral obesity therapy.

Key Decisions for Investors

• The robust efficacy and manageable safety data significantly de-risk the oral VK2735 program, supporting a bullish outlook as the asset advances toward pivotal Phase 3 studies.
• Investors should closely monitor the tolerability profile in future data, specifically the patient discontinuation rates at higher therapeutic doses, as this remains a key variable for commercial competitiveness against other GLP-1 agonists.
• The compelling trial results for an oral formulation substantially increase Viking's strategic value, and the potential for a partnership or acquisition by a larger pharmaceutical firm should be considered a primary catalyst.
• The positive proof-of-concept for a lower-dose weight maintenance regimen presents a compelling commercial advantage for long-term therapy, a factor that should be incorporated into valuation models.